CF
Therapeutic Areas
Apellis Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| SYFOVRE (pegcetacoplan) | Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration | Approved |
| EMPAVELI/Aspaveli (pegcetacoplan) | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Approved |
| Pegcetacoplan | C3 Glomerulopathy (C3G) / Primary Immune Complex-Mediated Membranoproliferative Glomerulonephritis (IC-MPGN) | Phase 3 |
| Systemic C3 inhibitor (next-gen) | Undisclosed complement-mediated diseases | Preclinical |
| Intravitreal C3 inhibitor (next-gen) | Undisclosed retinal diseases | Preclinical |
Leadership Team at Apellis Pharmaceuticals
CB
Caroline Baumal, MD
Chief Medical Officer
KB
Kelley Boucher
Chief People Officer
MD
Mark DeLong
Chief Business & Strategy Officer
PD
Pascal Deschatelets, PhD
Co-Founder & Chief Scientific Officer
LM
Leslie Meltzer, PhD
Chief Research & Development Officer
NN
Nur Nicholson
Chief Technical Operations Officer
TS
Timothy Sullivan
Chief Financial Officer
DW
David Watson, JD
General Counsel
GC
Gerald Chan, SD
Chairman of the Board
MD
Mikael Dolsten, MD, PhD
Director